Venus Remedies Limited , a leading research based global pharmaceutical company has come up with a platform technology called Drug -Protein-Polymer- Conjugate (DPPC). DPPC concept by Venus is a novel, patent protected technology, which will help in alleviating cancer and receptor diseases by a specific and selective targeting.
Revealing about this novel platform technology, Dr. Mufti Suhail Sayeed, Vice President- VMRC, Venus Remedies Limited said, “We at Venus Medicine Research Centre have designed a platform technology with a novel concept of triple conjugate i.e., Drug -Protein-Polymer- Conjugate (DPPC). Triple conjugate employs a protein moiety capable of binding selectively to a particular target site (affected organ), a polymer moiety covalently linked to a protein, and an active drug moiety. Based on specificity of the target organ, various components of DPPC can be rationally selected.”
Applauding her team on this achievement, Dr. (Mrs) Manu Chaudhary, Joint Managing Director and Director- Research, Venus Remedies Limited said, “This platform technology holds its essence, with its significant potential to conjugate a wide range of drugs (physiochemically different) thereby not only reducing the amount of the drug to be targeted but will also be very cost-effective.”
Commenting on this Pawan Chaudhary, CMD, Venus Remedies said, “The demonstrable efficacy in pre-clinical proof of concept studies and an imminent entry into clinical phase of the first DPPC based therapy is commendable achievement of team VMRC.”
He further added that we are very keen to bring this wonder therapy to the market for the benefit of the mankind and are seeking appropriate collaborations for co-development or technology commercialization of the therapy.
At present, the market is flooded with a number of drugs that are available for the cancer treatment such as monoclonal antibodies (Mab) and small molecule inhibitors. Mabs are not administered as first line therapy but are usually administered as a second or third line resorts, which are not always the same as the cancer cell-surface specific antigens to which they target, thus limiting their effectiveness. Apart from this, treatment with these drugs is costly, as the cost of development and therapy is very high and complicated. Also, it causes adverse effects such as breathlessness, flushes and faintness, change in blood pressure and sometimes fatal infections. Utility of monoclonal antibodies is further limited by a variable pharmacokinetic distribution and a limited ability to diffuse across the tumors.
Dr. (Mrs) Manu Chaudhary further added, “While providing some relief, these drugs also cause serious side effects to the patients as they tend to damage the healthy cells along with the cancerous cells. Keeping these issues in mind, Venus has come up a platform technology that would bring revolution to the existing target based therapies, with its pronounced therapeutic efficacy, reduced side effects due to a reduction in dose by 4-6 times. It would be a life saving drug within reach of the common man.”